D

DOD Biotech PCL
SET:DOD

Watchlist Manager
DOD Biotech PCL
SET:DOD
Watchlist
Price: 1.66 THB -1.19%
Market Cap: 720.6m THB
Have any thoughts about
DOD Biotech PCL?
Write Note

Income Statement

Earnings Waterfall
DOD Biotech PCL

Revenue
683m THB
Cost of Revenue
-464m THB
Gross Profit
219m THB
Operating Expenses
-359.2m THB
Operating Income
-140.2m THB
Other Expenses
-14.5m THB
Net Income
-154.7m THB

Income Statement
DOD Biotech PCL

Rotate your device to view
Income Statement
Currency: THB
Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
360
N/A
367
+2%
387
+6%
505
+30%
620
+23%
700
+13%
666
-5%
572
-14%
465
-19%
526
+13%
790
+50%
1 011
+28%
1 315
+30%
1 387
+6%
1 077
-22%
1 457
+35%
1 275
-13%
1 169
-8%
1 015
-13%
821
-19%
706
-14%
686
-3%
537
-22%
494
-8%
536
+9%
571
+7%
678
+19%
731
+8%
710
-3%
683
-4%
Gross Profit
Cost of Revenue
(165)
(165)
(155)
(190)
(234)
(260)
(257)
(226)
(194)
(246)
(380)
(473)
(666)
(726)
(616)
(811)
(711)
(654)
(581)
(511)
(454)
(461)
(397)
(368)
(384)
(378)
(415)
(442)
(472)
(464)
Gross Profit
195
N/A
202
+4%
232
+15%
315
+36%
386
+22%
440
+14%
410
-7%
346
-15%
271
-22%
280
+3%
410
+47%
538
+31%
649
+21%
661
+2%
461
-30%
646
+40%
564
-13%
514
-9%
435
-16%
309
-29%
252
-19%
225
-11%
141
-38%
126
-10%
151
+20%
193
+27%
263
+36%
289
+10%
238
-18%
219
-8%
Operating Income
Operating Expenses
(72)
(72)
(83)
(86)
(99)
(106)
(105)
(103)
(114)
(179)
(324)
(418)
(487)
(420)
(104)
(185)
(109)
(115)
(124)
(139)
(147)
(147)
(152)
(562)
(569)
(592)
(206)
(212)
(372)
(359)
Selling, General & Administrative
(73)
(73)
(83)
(87)
(100)
(107)
(105)
(112)
(124)
(192)
(330)
(425)
(490)
(427)
(107)
(189)
(111)
(117)
(127)
(143)
(153)
(157)
(158)
(173)
(192)
(218)
(248)
(268)
(272)
(257)
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(5)
0
0
0
0
0
0
0
Other Operating Expenses
1
1
0
1
1
1
0
10
10
12
6
8
2
7
3
4
1
2
3
3
6
10
11
(389)
(377)
(374)
42
56
(100)
(102)
Operating Income
123
N/A
130
+6%
149
+15%
229
+53%
287
+25%
334
+16%
305
-9%
244
-20%
158
-35%
101
-36%
86
-14%
121
+40%
162
+34%
242
+49%
357
+48%
461
+29%
454
-1%
399
-12%
311
-22%
170
-45%
105
-38%
78
-26%
(11)
N/A
(436)
-3 735%
(418)
+4%
(399)
+5%
57
N/A
78
+37%
(134)
N/A
(140)
-5%
Pre-Tax Income
Interest Income Expense
(3)
(3)
(4)
(4)
(3)
(4)
(4)
(5)
(14)
(15)
(8)
(59)
(41)
(39)
(21)
34
19
20
3
(10)
(6)
(8)
(7)
(8)
(8)
(8)
(8)
(8)
(7)
(6)
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
0
0
(7)
0
(7)
(11)
(2)
(52)
(52)
(49)
(51)
(1)
(0)
(406)
0
0
0
0
0
0
0
Total Other Income
(1)
(1)
1
(1)
(1)
(1)
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
120
N/A
127
+5%
147
+16%
225
+53%
284
+26%
330
+16%
308
-7%
238
-22%
144
-40%
86
-40%
78
-9%
55
-30%
121
+119%
196
+62%
325
+66%
493
+52%
422
-14%
367
-13%
265
-28%
108
-59%
98
-9%
70
-29%
(424)
N/A
(444)
-5%
(426)
+4%
(407)
+4%
49
N/A
70
+43%
(141)
N/A
(146)
-4%
Net Income
Tax Provision
3
3
(5)
(6)
(6)
(7)
(2)
(3)
(3)
(3)
(5)
4
(2)
(8)
(34)
(48)
(38)
(42)
(32)
(32)
(34)
(27)
79
79
67
60
(28)
(32)
(23)
(13)
Income from Continuing Operations
123
130
142
220
278
323
305
235
140
82
74
59
119
188
291
445
383
326
233
76
64
42
(345)
(365)
(359)
(347)
21
38
(164)
(160)
Income to Minority Interest
0
0
0
0
0
0
0
(0)
1
6
13
14
13
8
(11)
(11)
(10)
(9)
4
4
5
3
2
3
0
(1)
(1)
(0)
27
26
Net Income (Common)
123
N/A
130
+6%
142
+9%
220
+55%
278
+26%
323
+16%
305
-6%
235
-23%
141
-40%
88
-37%
87
-2%
73
-15%
131
+79%
181
+38%
141
-22%
168
+19%
35
-79%
(13)
N/A
50
N/A
(6)
N/A
26
N/A
4
-83%
(398)
N/A
(404)
-1%
(373)
+8%
(363)
+3%
7
N/A
25
+246%
(152)
N/A
(155)
-2%
EPS (Diluted)
0.41
N/A
0.43
+5%
0.47
+9%
0.73
+55%
0.86
+18%
0.78
-9%
0.85
+9%
0.57
-33%
0.35
-39%
0.22
-37%
0.21
-5%
0.18
-14%
0.32
+78%
0.44
+38%
0.34
-23%
0.41
+21%
0.08
-80%
-0.03
N/A
0.12
N/A
-0.01
N/A
0.06
N/A
0.01
-83%
-0.96
N/A
-0.98
-2%
-0.87
+11%
-0.8
+8%
0.01
N/A
0.09
+800%
-0.33
N/A
-0.34
-3%

See Also

Discover More